The proliferative status of CD4-8- thymocyte subsets was determined by in vivo or in vitro labeling with bromodeoxyuridine (BrdUrd), a nonreutilized thymidine analogue detectable with a monoclonal antibody, simultaneously with relevant surface proteins. An actively cycling subset [J11d+, interleukin 2 receptor-positive (IL 2R+)] was defined, besides a relatively resting one (J11d-, Pgp1+, T cell receptor-positive). Continuous per os administration of BrdUrd showed that 85% only of CD4-8- thymocytes were labeled in 6 days confirming the existence of a relatively long-term resting subset. By contrast, CD4+8+ thymocytes were all labeled in 3-4 days. Observation of labeled CD4-8- cells after pulse labeling showed an immediate decrease of their absolute number per thymus, confirming their low autorenewal capacity. However, a small number of labeled cells which were hydroxyurea or colchicine resistant remained CD4-8- for several days and progressively acquired surface expression of IL 2R. IL 2R expression by cycling CD4-8- cells during thymus regeneration after antimitogenic drug treatment was rapid, but very transient. According to these results most CD4-8- thymocytes appear as largely engaged in a proliferation-dependent differentiative process, and do not behave as true stem cells. Consequently, this subset is principally renewed by thymic immigration of exogenously produced resting cells. However, a tenfold expansion of CD4-8- cells was found in the fetal and regenerating thymus, suggesting two proliferative phases during intrathymic CD4-8- cell maturation, the first one yielding to cell expansion and the second to cell differentiation. A tentative evaluation of daily cell immigration is proposed starting with the determination of the number of cells beginning DNA synthesis each day. A global model is finally discussed by confronting our kinetic results with the known reconstitution capacities of CD4-8- thymocyte subsets.